Laurus Labs Limited (LAURUSLABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has a cash flow conversion efficiency ratio of 0.222x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs10.93 Billion ≈ $118.22 Million USD) by net assets (Rs49.34 Billion ≈ $533.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LAURUSLABS market cap overview for the company's overall valuation and market capitalisation.
Laurus Labs Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Laurus Labs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Laurus Labs Limited ranked by their cash flow conversion efficiency. Explore earnings quality score of Laurus Labs Limited to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guidewire Software Inc
NYSE:GWRE
|
0.074x |
|
Astra International Tbk
JK:ASII
|
0.035x |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
0.164x |
|
BJs Wholesale Club Holdings Inc
NYSE:BJ
|
0.066x |
|
S-Oil Corp
KO:010950
|
0.209x |
|
Fidelity National Financial Inc
NYSE:FNF
|
0.212x |
|
MILLICOM INTL CELL. DL15
F:M4M1
|
0.132x |
|
Metso Oyj
HE:METSO
|
0.054x |
Annual Cash Flow Conversion Efficiency for Laurus Labs Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Laurus Labs Limited from 2013 to 2025. View latest Laurus Labs Limited stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs46.03 Billion ≈ $497.75 Million |
Rs6.02 Billion ≈ $65.07 Million |
0.131x | -19.18% |
| 2024-03-31 | Rs41.16 Billion ≈ $445.08 Million |
Rs6.66 Billion ≈ $71.99 Million |
0.162x | -34.11% |
| 2023-03-31 | Rs40.49 Billion ≈ $437.85 Million |
Rs9.94 Billion ≈ $107.49 Million |
0.245x | -9.49% |
| 2022-03-31 | Rs33.59 Billion ≈ $363.27 Million |
Rs9.11 Billion ≈ $98.53 Million |
0.271x | -3.76% |
| 2021-03-31 | Rs26.01 Billion ≈ $281.26 Million |
Rs7.33 Billion ≈ $79.27 Million |
0.282x | +43.58% |
| 2020-03-31 | Rs17.70 Billion ≈ $191.39 Million |
Rs3.47 Billion ≈ $37.57 Million |
0.196x | +2.77% |
| 2019-03-31 | Rs15.58 Billion ≈ $168.54 Million |
Rs2.98 Billion ≈ $32.19 Million |
0.191x | -17.32% |
| 2018-03-31 | Rs14.83 Billion ≈ $160.34 Million |
Rs3.42 Billion ≈ $37.04 Million |
0.231x | -7.42% |
| 2017-03-31 | Rs13.30 Billion ≈ $143.88 Million |
Rs3.32 Billion ≈ $35.90 Million |
0.250x | +9.96% |
| 2016-03-31 | Rs8.52 Billion ≈ $92.12 Million |
Rs1.93 Billion ≈ $20.90 Million |
0.227x | +352.81% |
| 2015-03-31 | Rs7.21 Billion ≈ $77.96 Million |
Rs-647.06 Million ≈ $-7.00 Million |
-0.090x | -126.54% |
| 2014-03-31 | Rs3.58 Billion ≈ $38.76 Million |
Rs1.21 Billion ≈ $13.11 Million |
0.338x | -0.57% |
| 2013-03-31 | Rs2.59 Billion ≈ $28.04 Million |
Rs882.08 Million ≈ $9.54 Million |
0.340x | -- |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more